Show Summary Details
Page of

First-line hormonal therapy for metastatic prostate cancer 

First-line hormonal therapy for metastatic prostate cancer
First-line hormonal therapy for metastatic prostate cancer

Ajjai S Alva

and Maha Hussain

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 16 July 2018

Androgen deprivation therapy ((ADT) gonadal suppression) is the standard first line therapy for patients with metastatic prostate cancer. This can be accomplished medically with the use of an LHRH-agonist or antagonist or by bilateral orchiectomy

The addition of an anti-androgen (short course or continuous) must be individualized taking into account symptoms, sides effects, and costs of therapy

Pending results of completed randomized trials, intermittent androgen deprivation therapy can be used but is considered experimental

Physicians managing patients should attend to the long-term toxicity from ADT, particularly effect on BMD and the metabolic syndromes

Considering the inevitability of progression in virtually all patients undergoing ADT, new treatment strategies targeting mechanisms of progression are an active area of investigation.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.